Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Karyopharm Therapeutics Inc. - Common Stock
(NQ:
KPTI
)
1.910
+0.090 (+4.95%)
Streaming Delayed Price
Updated: 11:10 AM EDT, Aug 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Karyopharm Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
↗
August 20, 2026
Biotech pivots to hematology after endometrial cancer setback, faces debt deadline.
Via
The Motley Fool
Topics
Earnings
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
↗
August 13, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is...
Via
Benzinga
Topics
Earnings
Top movers in Friday's session
↗
July 31, 2026
Via
Chartmill
Top stock movements in today's session.
↗
July 31, 2026
Via
Chartmill
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Posts Q1 Beat and Highlights ASCO Presentation, Shares Surge 7%
↗
May 14, 2026
Via
Chartmill
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Q4 Revenue Miss and Wider Loss, Stock Falls in Pre-Market
↗
February 12, 2026
Via
Chartmill
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
Gapping stocks in Friday's session
↗
July 31, 2026
Via
Chartmill
Friday's pre-market session: top gainers and losers
↗
July 31, 2026
Via
Chartmill
Thursday's after hours session: top gainers and losers
↗
July 30, 2026
Via
Chartmill
Which stocks are moving on Monday?
↗
July 20, 2026
Via
Chartmill
Karyopharm Therapeutics Earnings Preview
↗
October 31, 2025
Via
Benzinga
Earnings Outlook For Karyopharm Therapeutics
↗
August 08, 2025
Via
Benzinga
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts
↗
May 26, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral...
Via
MarketBeat
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus
↗
May 26, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO...
Via
MarketBeat
Karyopharm (KPTI) Q1 2026 Earnings Transcript
↗
May 14, 2026
Karyopharm (KPTI) Q1 2026 Earnings Transcript
Via
The Motley Fool
Karyopharm Therapeutics Q1 Earnings Call Highlights
↗
May 14, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in...
Via
MarketBeat
Topics
Earnings
Karyopharm (KPTI) Q2 2025 Earnings Transcript
↗
May 04, 2026
Karyopharm (KPTI) Q2 2025 Earnings Transcript
Via
The Motley Fool
Karyopharm (KPTI) Q1 2025 Earnings Transcript
↗
May 04, 2026
Karyopharm (KPTI) Q1 2025 Earnings Transcript
Via
The Motley Fool
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript
↗
February 12, 2026
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Derivatives
Earnings
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Q3 2025 Revenue Beat and Earnings Miss
↗
November 03, 2025
Karyopharm (KPTI) Q3 2025 results show a revenue beat but an earnings miss. The stock rose pre-market as investors focus on XPOVIO sales growth and key Phase 3 data due in 2026.
Via
Chartmill
Topics
Earnings
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
↗
October 13, 2025
Via
Benzinga
Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026
↗
October 08, 2025
Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 million Q3 revenue, and advances Phase 3 selinexor trial.
Via
Benzinga
These stocks that are showing activity before the opening bell on Wednesday.
↗
October 08, 2025
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 08, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
September 24, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
September 23, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 08, 2025
Via
Benzinga
Top movers analysis in the middle of the day on 2025-08-15: top gainers and losers in today's session.
↗
August 15, 2025
Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Earnings Scheduled For August 11, 2025
↗
August 11, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
